{
    "name": "oxandrolone",
    "comment": "Rx",
    "other_names": [
        "Oxandrin"
    ],
    "classes": [
        "Androgens"
    ],
    "source": "https://reference.medscape.com/drug/oxandrin-oxandrolone-342889",
    "pregnancy": {
        "common": [
            "Shown to cause embryotoxicity, fetotoxicity, infertility, and masculinization of female animal offspring when given in doses 9 times the human dose; contraindicated in pregnancy"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not known whether anabolic steroids are excreted in human milk; because of potential of serious adverse reactions in nursing infants from this drug, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Peliosis Hepatis",
                    "description": [
                        " Peliosis hepatitis has been reported with androgenic anabolic steroid therapy  In this condition, the liver & sometimes splenic tissue is replaced with blood-filled cysts",
                        "These cysts sometimes present with minimal hepatic dysfunction but have been associated with liver failure",
                        "Often not detected until life-threatening liver failure or intra-abdominal hemorrhage develops",
                        "Discontinuing an anabolic steroid usually results in complete disappearance of lesions"
                    ]
                },
                {
                    "type": "Liver Cell Tumors",
                    "description": [
                        "Liver cell tumors have been reported",
                        "Typically, these tumors are benign & androgen-dependent, but fatal malignant tumors have been reported",
                        "Discontinuing anabolic steroids often result in regression or arrested progression of tumor",
                        "Important to recognize that hepatic tumors associated w/ metabolic-endocrine#androgens or anabolic steroids are much more vascular than other hepatic tumors & may be silent until life-threatening intra-abdominal hemorrhage develops"
                    ]
                },
                {
                    "type": "Blood Lipid Changes",
                    "description": [
                        " May cause blood lipid changes associated w/ increased risk of atherosclerosis",
                        "Lipid changes include decreased HDL & sometimes increased LDL; changes may be very marked & could have serious impact on risk for atherosclerosis & coronary artery disease"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Known or suspected prostate or breast CA in males",
                "Females: breast cancer with hypercalcemia",
                "Pregnancy",
                "Nephrosis or the nephrotic phase of nephritis",
                "Hypercalcemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Androgenic anabolic steroids may stimulate osteolytic bone resorption; contraindicated in carcinoma of the breast in females with hypercalcemia",
                "Cholestatic hepatitis and jaundice may occur with 17-alpha-alkylated metabolic-endocrine#androgens at a relatively low dose; if cholestatic hepatitis with jaundice appears or if liver function tests become abnormal, this drug should be discontinued and the etiology determined; drug-induced jaundice is reversible when medication is discontinued",
                "In patients with breast cancer, anabolic steroid therapy may cause hypercalcemia by stimulating osteolysis; this drug should be discontinued if hypercalcemia occurs",
                "Edema with or without congestive heart failure may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease; concomitant administration of adrenal cortical steroid or ACTH may increase the edema",
                "In children, androgen therapy may accelerate bone maturation without producing compensatory gain in linear growth; this adverse effect results in compromised adult height; the younger the child, the greater the risk of compromising final mature height",
                "Effect on bone maturation should be monitored by assessing bone age of left wrist and hand every 6 months",
                "Geriatric patients treated with androgenic anabolic steroids may be at an increased risk for development of prostatic hypertrophy and prostatic carcinoma",
                "Concurrent dosing with warfarin may result in unexpectedly large increases in the International Normalized Ratio (INR) or prothrombin time (PT); when prescribed to patients being treated with warfarin, doses of warfarin may need to be decreased significantly to maintain desirable INR level and diminish risk of potentially serious bleeding",
                "Women should be observed for signs of virilization (deepening of voice, hirsutism, acne, clitoromegaly); discontinuation of drug therapy at time of evidence of mild virilism is necessary to prevent irreversible virilization",
                "Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens; menstrual irregularities may also occur",
                "Anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time",
                "Does not improve athletic performance"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "oxandrolone increases effects of cyclosporine by decreasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "oxandrolone and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pretomanid",
            "description": {
                "common": "oxandrolone, pretomanid.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "warfarin",
            "description": {
                "common": "oxandrolone increases effects of warfarin by anticoagulation. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "oxandrolone increases toxicity of carbamazepine by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acarbose",
            "description": {
                "common": "oxandrolone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "androstenedione",
            "description": {
                "common": "androstenedione increases effects of oxandrolone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "budesonide",
            "description": {
                "common": "oxandrolone, budesonide.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "oxandrolone increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cortisone",
            "description": {
                "common": "oxandrolone, cortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "deflazacort",
            "description": {
                "common": "oxandrolone, deflazacort.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "oxandrolone, dexamethasone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epoetin alfa",
            "description": {
                "common": "oxandrolone increases effects of epoetin alfa by pharmacodynamic synergism. Minor/Significance Unknown. Androgens may be used to decrease necessary dose of epoetin alfa."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "oxandrolone, fludrocortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "oxandrolone increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "oxandrolone increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "oxandrolone increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "oxandrolone, hydrocortisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "oxandrolone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "oxandrolone increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "oxandrolone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "oxandrolone increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "oxandrolone increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "oxandrolone increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "oxandrolone increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "oxandrolone increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "oxandrolone, methylprednisolone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miglitol",
            "description": {
                "common": "oxandrolone increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nateglinide",
            "description": {
                "common": "oxandrolone increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "oxandrolone increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisolone",
            "description": {
                "common": "oxandrolone, prednisolone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prednisone",
            "description": {
                "common": "oxandrolone, prednisone.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "oxandrolone increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "oxandrolone increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saw palmetto",
            "description": {
                "common": "saw palmetto decreases effects of oxandrolone by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "oxandrolone increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "oxandrolone increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "oxandrolone increases effects of tacrolimus by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "oxandrolone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "oxandrolone increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "oxandrolone, triamcinolone acetonide injectable suspension.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. May enhance edema formation."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "oxandrolone increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Gynecomastia",
            "percent": null
        },
        {
            "name": "Inhibition of testicular function",
            "percent": null
        },
        {
            "name": "Impotence",
            "percent": null
        },
        {
            "name": "Priapism",
            "percent": null
        },
        {
            "name": "Bladder irritability",
            "percent": null
        },
        {
            "name": "Hirsutism",
            "percent": null
        },
        {
            "name": "Male",
            "percent": null
        },
        {
            "name": "pattern baldness",
            "percent": null
        },
        {
            "name": "Menstrual irregularities",
            "percent": null
        },
        {
            "name": "Virilism",
            "percent": null
        },
        {
            "name": "Neoplasm of liver",
            "percent": null
        },
        {
            "name": "Peliosis hepatis",
            "percent": null
        },
        {
            "name": "Premature epiphyseal closure",
            "percent": null
        },
        {
            "name": "Children",
            "percent": null
        }
    ]
}